Catalent

Short description: American pharmaceutical company

Catalent, Inc.

Type| Public company

Traded as

* NYSE: CTLT
* S&P 500 component

Industry| Pharmaceuticals
Predecessor| Cardinal Health PTS
Founded| 2007
Headquarters| Somerset, New Jersey, U.S.

Number of locations

| 49 (2020)[1]

Key people

Alessandro Maselli
(President, CEO & Director),
Matti Masanovich
(CFO)
Services| Drug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain, regulatory consulting
Revenue|  US$4.828 Billion (Fiscal Year Ended June 30, 2022)[2]

Operating income

|  US$0.756 Billion (Fiscal Year Ended June 30, 2022)[2]

Net income

|  US$0.519 Billion (Fiscal Year Ended June 30, 2022)[2]
Total assets|  US$10.507 Billion (Fiscal Year Ended June 30, 2022)[2]
Total equity|  US$4.795 Billion (Fiscal Year Ended June 30, 2022)[2]

Number of employees

| 14,000 (2020)
Website| catalent.com

Catalent, Inc. (Catalent Pharma Solutions) is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people,[3] including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.[1]

Catalent was formed in April 2007 when affiliates of the Blackstone Group L.P. acquired the core of the pharmaceutical technologies and services (PTS) segment of Cardinal Health, Inc.[4] Cardinal Health created PTS through a series of acquisitions starting with R.P. Scherer Corporation in 1998.[5]

In 2014, Catalent became a public company, listed on the New York Stock Exchange.

## Contents

* 1 History
* 1.1 Before 2007
* 1.2 Formation of Catalent in 2007
* 1.3 After 2007 and initial public offering-2019
* 1.4 2020-present
* 2 Financials
* 3 References
* 4 External links

## History

### Before 2007

In 1996, Cardinal Health acquired PCI (Headquarters: Philadelphia, Pennsylvania).[6] PCI (Packaging Coordinators Inc.) is a pharmaceutical contract packing service for commercial and clinical packaging.[7]

In 1998, Cardinal Health acquired R.P. Scherer Corporation (Headquarters: Troy, Michigan).[8] Robert Pauli Scherer founded the R.P. Scherer Corporation to commercialize his innovation of softgel encapsulation using the rotary die production process.[9] The following year, in 1999, Cardinal Health acquired Automatic Liquid Packaging, Inc. (Headquarters: Woodstock, Ill.),[6] whose Blow-Fill-Seal Technology allowed Cardinal to enter the sterile product market.[9]

In 2001, Cardinal Health acquired International Processing Corporation, a company that was renowned for its expertise in oral modified-release dosage form development and manufacturing. In 2002, Cardinal Health acquired Magellan Laboratories Inc., a company that specialized in product development expertise.[6] In 2003, Cardinal Health acquired Gala Biotech (Headquarters: Madison, Wisconsin).[6] In the same year, Cardinal Health also acquired Intercare Group PLC, broadening its global capabilities in Europe.[6]

From 2004 to 2006, Cardinal Health further expanded its reach in biotechnology and pharmaceutical markets through multiple acquisitions.[6]

### Formation of Catalent in 2007

In 2007, the pharmaceutical technologies and services segment of Cardinal Health was purchased by Blackstone Group and re-branded as Catalent Pharma Solutions.[4]

### After 2007 and initial public offering-2019

In 2012, Catalent acquired Aptuit, a clinical supply company. As part of the deal, Catalent gained three sites in the US, two in the UK, and one in Singapore.[10] Catalent also acquired all remaining shares for the R.P Scherer site in Eberbach, Germany.[8][11][12] In 2013, Catalent continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology Co, a China-based company, and Relthy Laboratories in Brazil.[13]

Catalent announced its initial public offering in July 2014. After raising more than $870 million, Catalent became a publicly traded company on the New York Stock Exchange (NYSE).[14] The company priced its 42.5 million shares of common stock at $20.50 apiece, with a market capitalization of $2.4 billion. The shares began trading on the NYSE on 31 July 2014, under the ticker symbol CTLT.[14]

In November 2014, Catalent announced it had acquired Micron Technologies, a provider of particle size engineering technologies.[15] The acquisition allowed Catalent to expand its portfolio of drug delivery technologies.[15]

In 2016, Catalent licensed the anti-body drug conjugate (ADC) to Triphase Accelerator to help with oncology development,[16] and bought Pharmatek Laboratories to add spray drying to their manufacturing capabilities.[17] In September 2017, Catalent agreed to acquire Cook Pharmica for $950 million, allowing Catalent to expand their biologic manufacturing.[18] In July 2018, Catalent extended their work with Juniper Pharmaceuticals with a $133 million deal.[19]

Alessandro Maselli was appointed as president and chief operating officer in 2019, a newly created position within Catalent.[20] In March, 2019, Catalent invested more than $27 million to commercialize Zydis Ultra. The investment includes new Zydis lines; changes to one of their facilities in Swindon, UK; and a custom suite for commercial equipment.[21] Later in 2019, Catalent partnered with GB Sciences to develop a cannabinoid-derived medicine for Parkinson's disease utilizing the Zydis delivery method.[22]

In April 2019, Catalent agreed to acquire Paragon Bioservices Inc for $1.2 billion to expand its gene-therapy manufacturing capabilities.[23] The deal was completed in May 2019 and included an agreement with Sarepta Therapeutics, a gene therapy manufacturer.[24] As of October 2019, Paragon's employee numbers have almost doubled since the April acquisition.[25]

In June 2019, Catalent acquired Bristol-Myers' European launch pad to expand its global CDMO.[26]

### 2020-present

In January 2020, Catalent purchased a manufacturing facility located in Anagni, Italy, from Bristol-Myers Squibb, to manufacture and package biologic and oral solid dose products for multiple companies.[27] In February 2020, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million. The acquisition allows Catalent to expand into cell therapy development.[28][29]

In 2020, Catalent partnered with multiple drugmakers, including Pfizer, Johnson & Johnson,[30] AstraZeneca,[31] and Moderna[32] to provide manufacturing, vial filling and packaging capabilities for COVID-19 vaccine candidates.[33][34] In the partnership with AstraZeneca, Catalent will provide manufacturing from its Maryland facility and vial filling and packaging from its Italian facility.[35] Catalent also partnered with ViralClear to manufacture a COVID-19 treatment candidate at Catalent's St. Petersburg facility.[36] Also in 2021, Catalent acquired German gene therapy development firm Rheincell Therapeutics.[37]

In August 2021, Catalent announced plans to acquire nutritional supplement company Bettera Holdings LLC for $1 billion. The deal will allow Catalent to manufacture vitamins, minerals and supplements in gummy form.[38]

In October 2021, Catalent opened a 6,000 square-meter clinical supply facility in Shiga, Japan.[39]

In October 2022, Catalent announced a $12M expansion at a Kansas City, MO facility.[40]

January 2023, Catalent partnered with Sarepta Therapeutics to manufacture delandistrogene moxeparvovec (SRP-9001). Sarepta's most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD).[41][42][43]

## Financials

Annual Financial Table[1] #  | 2016  | 2017  | 2018  | 2019  | 2020  | 2021 | 2022

|
|
|
|
|
|
|

Sales/Revenue  | 1.85B  | 2.08B  | 2.46B  | 2.52B  | 3.09B  | 3.998B  | 4.828B
Total Current Assets  | 3.09B  | 2.45B  | 4.53B  | 6.18B  | 7.78B  | 9.112B  | 10.507B
Net Operating Cash Flow  | 155.3M  | 299.5M  | 374.5M  | 247.7M  | 440.3M  | 0.585B  | 0.519B

## References

1. ↑ 1.0 1.1 1.2 "Catalent 2022 Annual Report". https://s201.q4cdn.com/269710127/files/doc_financials/2022/ar/2022-Catalent-Form-10-K-(29Aug2022)(as-filed).pdf.
2. ↑ 2.0 2.1 2.2 2.3 2.4 "Catalent, Inc. 2020 Annual Report". 30 June 2021. https://s23.q4cdn.com/220277989/files/doc_financials/2021/ar/2021-Catalent-Annual-Report-(final).pdf. Retrieved 10 October 2021.
3. ↑ "Catalent Boosts Supply Chain Transparency in Response to COVID-19 Manufacturing Urgency" (in en-US). https://www.biospace.com/article/catalent-boosts-supply-chain-transparency-in-response-to-covid-19-manufacturing-urgency/.
4. ↑ 4.0 4.1 "Cardinal Health Completes Sale of Pharmaceutical Technologies and Services Segment to The Blackstone Group". Dublin, Ohio: Blackstone Group. 10 April 2007. http://www.blackstone.com/news-views/press-releases/details/cardinal-health-completes-sale-of-pharmaceutical-technologies-and-services-segment-to-the-blackstone-group.
5. ↑ "Cardinal Health Agrees to Acquire Scherer for $2.07 Billion in Stock". The Wall Street Journal. 19 May 1998. https://www.wsj.com/articles/SB895506453762968500.
6. ↑ 6.0 6.1 6.2 6.3 6.4 6.5 "Cardinal Health's timeline -- CardinalHealth.com". Archived from the original on 11 April 2015. https://web.archive.org/web/20150411000112/http://extww02a.cardinal.com/us/en/aboutus/history/timeline/index.asp. Retrieved 7 April 2015.
7. ↑ "PCI leads the market in healthcare packaging solutions". http://pciservices.com/. Retrieved 7 April 2015.
8. ↑ 8.0 8.1 "Catalent completes acquisition of R P Scherer Eberbach". Manufacturing Chemist. 1 March 2012. http://www.manufacturingchemist.com/news/article_page/Catalent_completes_acquisition_of_R_P_Scherer_Eberbach/76286. Retrieved 7 April 2015.
9. ↑ 9.0 9.1 Kuehn, Steven (6 October 2014). "Container Innovation's Prairie Home". Pharmaceutical Manufacturing. http://www.pharmamanufacturing.com/articles/2014/container-innovations-prairie-home/. Retrieved 7 April 2015.
10. ↑ "Catalent completes Aptuit deal". BioPharma-reporter.com. 20 February 2012. http://www.biopharma-reporter.com/Bio-Developments/Catalent-completes-Aptuit-deal. Retrieved 7 April 2015.
11. ↑ Wasserman, Robert (2016-09-08). "2 big companies and 1 small one to target in the pharma/biotech space" (in en). https://www.thestreet.com/story/13697296/1/2-big-companies-and-1-small-one-to-target-in-the-pharma-biotech-space.html.
12. ↑ "Gelita and R.P. Scherer End 60 Year Joint Venture". https://fif.cnsmedia.com/a/eNnejRzm4IA=.
13. ↑ Stanton, Dan (10 October 2013). "Catalent's Brazilian acquisition supports global softgel strategy". inPharma-technologist.com. http://www.in-pharmatechnologist.com/Drug-Delivery/Catalent-s-Brazilian-acquisition-supports-global-softgel-strategy. Retrieved 7 April 2015.
14. ↑ 14.0 14.1 "Catalent Issues Initial Public Offering". Pharmaceutical Technology Sourcing and Management. PharmTech.com. 4 August 2014. http://www.pharmtech.com/catalent-issues-initial-public-offering. Retrieved 7 April 2015.
15. ↑ 15.0 15.1 "Catalent Acquires Micron Technologies, Adds Particle Engineering Capabilities to Portfolio". 13 November 2014. http://www.pharmtech.com/catalent-acquires-micron-technologies-adds-particle-engineering-capabilities-portfolio.
16. ↑ "Catalent out-licenses ADC to Triphase" (in en-US). https://www.biopharmadive.com/news/catalent-out-licenses-adc-to-triphase/427780/.
17. ↑ "Catalent Buys Pharmatek and Lands Spray Drying Technology". Pharmaceutical Investing News. 14 September 2016. https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/catalent-buys-pharmatek-spray-drying-technology/.
18. ↑ "Catalent targets biologics with Cook Pharmica acquisition" (in en-US). Pharmaceutical Commerce. Pharmaceutical Commerce - January/February 2009. 2017-09-19. https://pharmaceuticalcommerce.com/latest-news/catalent-targets-biologics-cook-pharmica-acquisition/. Retrieved 2019-11-21.
19. ↑ "Catalent extends expansion with $133M deal for Juniper Pharmaceuticals" (in en). Fierce Pharma. 3 July 2018. https://www.fiercepharma.com/manufacturing/catalent-extends-expansion-130m-deal-for-juniper-pharmaceuticals.
20. ↑ "Catalent Names Alessandro Maselli President and Chief Operating Officer" (in en-US). https://finance.yahoo.com/news/catalent-names-alessandro-maselli-president-120000487.html.
21. ↑ "Catalent Invests in Zydis Ultra Commercialization". 20 March 2019. http://www.pharmtech.com/catalent-invests-zydis-ultra-commercialization.
22. ↑ "Wellness products take off in the growing recreational cannabis market" (in en-US). 2019-10-01. https://mjbizmagazine.com/wellness-products-take-off-in-the-growing-recreational-cannabis-market/.
23. ↑ Hopkins, Kimberly Chin and Jared S. (15 April 2019). "Catalent to Buy Paragon Bioservices for $1.2 Billion" (in en-US). Wall Street Journal. https://www.wsj.com/articles/catalent-to-buy-paragon-bioservices-for-1-2-billion-11555330948.
24. ↑ "Catalent's new prize, Paragon, adding capacity to make Sarepta gene therapies" (in en). Fierce Pharma. 21 May 2019. https://www.fiercepharma.com/manufacturing/catalent-s-new-prize-paragon-adding-capacity-to-make-sarepta-gene-therapies.
25. ↑ "Paragon growing quickly toward 1,000 employees after Catalent acquisition". 17 October 2019. https://www.bizjournals.com/baltimore/news/2019/10/17/paragon-growing-quickly-toward-1-000-employees.html.
26. ↑ "'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops" (in en). https://endpts.com/its-a-growth-play-catalent-acquires-bristol-myers-european-launch-pad-expanding-global-cdmo-ops/.
27. ↑ "Bristol-Myers offloads manufacturing plant to Catalent". Outsourcing-Pharma. 13 January 2020. https://www.outsourcing-pharma.com/Article/2020/01/13/Bristol-Myers-offloads-manufacturing-plant-to-Catalent.
28. ↑ "Catalent laying out $315M to snatch another gene therapy CDMO". FiercePharma. https://www.fiercepharma.com/manufacturing/catalent-laying-out-315m-to-snatch-another-gene-therapy-cdmo.
29. ↑ "Catalent adds to regenerative therapy portfolio with $315m acquisition". Manufacturing Chemist. 3 February 2020. https://www.manufacturingchemist.com/news/article_page/Catalent_adds_to_regenerative_therapy_portfolio_with_315m_acquisition/162009.
30. ↑ "Pfizer to outsource some drug production, focus on coronavirus vaccine" (in en). 2020-05-09. https://www.cnbc.com/2020/05/08/pfizer-to-outsource-some-drug-production-focus-on-coronavirus-vaccine.html.
31. ↑ "AstraZeneca Picks Catalent for Packaging, Supplying Potential COVID-19 Vaccine" (in en-US). The New York Times. 2020-06-15. https://www.nytimes.com/reuters/2020/06/15/us/15reuters-health-coronavirus-astrazeneca-catalent.html.
32. ↑ "Moderna Is the Latest Coronavirus Vaccine Partner for Catalent" (in en-US). https://www.barrons.com/articles/moderna-coronavirus-vaccine-partner-catalent-production-51593099741.
33. ↑ "'Vaccine Nationalism': A New Dynamic in the Race to Quash Coronavirus" (in en-US). The Wall Street Journal. 2020-05-27. https://www.wsj.com/articles/geopolitical-power-play-over-coronavirus-vaccine-leaves-drugmakers-in-the-middle-11590577849.
34. ↑ "Vaccine makers face biggest medical manufacturing challenge in history" (in en). Reuters. 2020-06-25. https://www.reuters.com/article/us-health-coronavirus-vaccines-manufactu-idUSKBN23W1ND.
35. ↑ "AstraZeneca taps Catalent Inc. to manufacture Covid-19 vaccine candidate in Maryland". 26 August 2020. https://www.bizjournals.com/baltimore/news/2020/08/26/catalent-to-manufacture-covid-19-vaccine-in-md.html.
36. ↑ "Manufacturer to help develop potential Covid treatment at St. Pete facility". https://www.bizjournals.com/tampabay/news/2020/06/23/why-this-medical-company-partnered-with-a-st-pete.html.
37. ↑ "Catalent Finalizes RheinCell Therapeutics Acquisition". 6 August 2021. https://www.biopharminternational.com/view/catalent-finalizes-rheincell-therapeutics-acquisition.
38. ↑ Hopkins, Jared S. (2021-08-30). "WSJ News Exclusive | Catalent to Buy Supplement Maker Bettera Holdings for $1 Billion" (in en-US). Wall Street Journal. ISSN 0099-9660. https://www.wsj.com/articles/catalent-to-buy-supplement-maker-bettera-holdings-for-1-billion-11630274401.
39. ↑ "Catalent's Momentum Continues with Up to 600 New Jobs Being Added" (in en-US). https://www.biospace.com/article/crmo-catalent-on-a-roll-expects-to-add-500-to-600-jobs-in-indiana/.
40. ↑ "Catalent Announces $12 Million Expansion Program at Kansas City Facility". https://www.contractpharma.com/contents/view_breaking-news/2022-10-20/catalent-announces-12-million-expansion-program-at-kansas-city-facility/.
41. ↑ Keenan, Joseph (2023-01-05). "Catalent inks deal to manufacture Sarepta's DMD gene therapy" (in en). https://www.fiercepharma.com/manufacturing/catalent-inks-deal-manufacture-sareptas-dmd-gene-therapy.
42. ↑ "Sarepta marches forward with its potential DMD gene therapy and an expanded Catalent manufacturing deal" (in en). https://endpts.com/sarepta-signs-deal-with-catalent/.
43. ↑ "Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate" (in en). 2023-01-05. https://www.businesswire.com/news/home/20230105005445/en/Sarepta-and-Catalent-Expand-Strategic-Manufacturing-Partnership-With-Commercial-Supply-Agreement-for-Duchenne-Muscular-Dystrophy-Gene-Therapy-Candidate.

## External links

* Official website
* Business data for Catalent, Inc.:

* Google Finance
* Yahoo! Finance
* Bloomberg
* Reuters
* SEC filings

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Catalent. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Company:Catalent&oldid=1047228"